Samsung Bio and Rigachem Bio Sign MOU for ADC Business Collaboration
Expansion of Collaboration for ADC Therapeutic Development
Goal to Conduct More Than 3 Projects This Year
Samsung Biologics announced on the 9th that it has signed a business agreement with Ligand Chem Biosciences to collaborate on the antibody-drug conjugate (ADC) business. Through this agreement, the two companies plan to cooperate on more than three ADC projects this year.
ADC is an anticancer drug in which an antibody and a drug are chemically linked through a connecting material called a linker, possessing the characteristic of attacking only the targeted cancer cells.
John Rim, CEO of Samsung Biologics, stated, "We will collaborate with Ligand Chem Bio to provide high-quality ADC pharmaceuticals to patients."
Hot Picks Today
!["Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2025050713592847164_1746593968.jpg)
"Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Do We Need to Panic Buy Again?" War Drives 30% Price Surge... Even the Bedroom Feels the Impact
- "As Soon as We Hit Something, It Burst"... 13 Cars Damaged While Driving at Night
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Jay Y. Lee Bows His Head: "I Will Take All the Blame"... Apologizes for Samsung Labor-Management Conflict
Kim Yong-joo, CEO of Ligand Chem Bio, said, "Starting this year, we expect to begin receiving royalties in earnest," adding, "Based on this, we will aggressively invest in research and development (R&D) to discover more than 15 clinical pipelines within five years."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
